Peter Carroll is a notable inventor based in San Francisco, CA. He has made significant strides in the field of cancer treatment, holding a total of 5 patents. His work focuses on understanding and targeting the adaptive responses of tumors to protein synthesis stress, particularly in prostate cancer.

Latest Patents

One of Peter Carroll's latest patents addresses cancer treatment targeted to tumor adaptive responses to protein synthesis stress. In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2α axis of the UPR adaptive response. Agents that disrupt PERK-eIF2α pathways can lead to cancer cell death from uncontrolled growth. For example, ISRIB and its derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally, PTEN loss and activation of Myc provide a diagnostic marker that enables better prognosis and the selection of amenable treatments.

Career Highlights

Peter Carroll is affiliated with the University of California, where he continues to contribute to groundbreaking research in cancer treatment. His innovative approaches have garnered attention in the scientific community, leading to advancements in therapeutic strategies.

Collaborations

Some of his notable coworkers include Tom F Lue and Ching-Shwun Lin, who have collaborated with him on various research projects.

Conclusion

Peter Carroll's work exemplifies the impact of innovative thinking in the medical field, particularly in cancer treatment. His contributions are paving the way for new therapeutic strategies that could significantly improve patient outcomes.